- Home
- VERO vs GRI Comparison
VERO vs GRI Comparison
Compare VERO & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VERO
- GRI
- Stock Information
- Founded
- VERO N/A
- GRI 2018
- Country
- VERO Canada
- GRI United States
- Employees
- VERO N/A
- GRI N/A
- Industry
- VERO Medical/Dental Instruments
- GRI Biotechnology: Pharmaceutical Preparations
- Sector
- VERO Health Care
- GRI Health Care
- Exchange
- VERO Nasdaq
- GRI Nasdaq
- Market Cap
- VERO 3.1M
- GRI 3.0M
- IPO Year
- VERO N/A
- GRI N/A
- Fundamental
- Price
- VERO $0.31
- GRI $0.77
- Analyst Decision
- VERO
- GRI Strong Buy
- Analyst Count
- VERO 0
- GRI 1
- Target Price
- VERO N/A
- GRI $12.00
- AVG Volume (30 Days)
- VERO 2.3M
- GRI 9.9M
- Earning Date
- VERO 11-13-2024
- GRI 11-14-2024
- Dividend Yield
- VERO N/A
- GRI N/A
- EPS Growth
- VERO N/A
- GRI N/A
- EPS
- VERO N/A
- GRI N/A
- Revenue
- VERO $67,200,000.00
- GRI N/A
- Revenue This Year
- VERO N/A
- GRI N/A
- Revenue Next Year
- VERO $7.56
- GRI N/A
- P/E Ratio
- VERO N/A
- GRI N/A
- Revenue Growth
- VERO N/A
- GRI N/A
- 52 Week Low
- VERO $0.28
- GRI $0.30
- 52 Week High
- VERO $2.22
- GRI $106.29
- Technical
- Relative Strength Index (RSI)
- VERO 34.77
- GRI 49.32
- Support Level
- VERO $0.38
- GRI $0.79
- Resistance Level
- VERO $0.44
- GRI $1.00
- Average True Range (ATR)
- VERO 0.07
- GRI 0.17
- MACD
- VERO -0.01
- GRI -0.02
- Stochastic Oscillator
- VERO 7.27
- GRI 24.95
About VERO Venus Concept Inc.
Venus Concept Inc is a medical technology company. It develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies and related services. The company's products include NeoGraft, Venus Viva, Venus Legacy, Venus Versa, Venus Velocity, Venus Bliss, ARTAS systems, and others. The company provides medical devices and treatments for hair, body, and skin-related problems. It generates a majority of its revenue from the United States.
About GRI GRI Bio Inc.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist, for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.